Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.

[1]  D. Aarsland,et al.  Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  K. Cain,et al.  Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. , 2014, The American journal of pathology.

[3]  Leslie M. Shaw,et al.  Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls , 2017, Neurology.

[4]  B. Mollenhauer,et al.  Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.

[5]  Tormod Fladby,et al.  A Practical Guide to Immunoassay Method Validation , 2015, Front. Neurol..

[6]  L. Rapport,et al.  Validation of the Warrington theory of visual processing and the Visual Object and Space Perception Battery. , 1998, Journal of clinical and experimental neuropsychology.

[7]  K. Blennow,et al.  Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. , 2012, Archives of neurology.

[8]  B. Mollenhauer,et al.  Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases , 2017, Alzheimer's & Dementia.

[9]  H. Vankova.  Mini Mental State , 2010 .

[10]  K. Blennow,et al.  Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[11]  K. Blennow,et al.  Validation of a new assay for α-synuclein detection in cerebrospinal fluid , 2017, Clinical chemistry and laboratory medicine.

[12]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[13]  Takahiko Tokuda,et al.  Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease , 2016, Molecular Neurodegeneration.

[14]  K. Blennow,et al.  Amyloid biomarkers in Alzheimer's disease. , 2015, Trends in pharmacological sciences.

[15]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[16]  J. Molinuevo,et al.  Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease , 2015, Journal of Neurology.

[17]  Henrik Zetterberg,et al.  CSF Aβ42 predicts early-onset dementia in Parkinson disease , 2014, Neurology.

[18]  P. Calabresi,et al.  Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression , 2016, Movement disorders : official journal of the Movement Disorder Society.

[19]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[20]  Diane C. Tsai.  Recent Developments in Parkinson's Disease , 1986, The Yale Journal of Biology and Medicine.

[21]  A. Ludolph,et al.  Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer′s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies* , 2016, Molecular & Cellular Proteomics.

[22]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[23]  Magda Tsolaki,et al.  Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases , 2015, Nature Reviews Neurology.

[24]  Federica Scarpina,et al.  The Stroop Color and Word Test , 2017, Front. Psychol..

[25]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[26]  A J Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study , 2001, Neurology.

[27]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[28]  M. Xilouri,et al.  Alpha-synuclein and Protein Degradation Systems: a Reciprocal Relationship , 2012, Molecular Neurobiology.

[29]  Peter Gluchowski,et al.  F , 1934, The Herodotus Encyclopedia.

[30]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[31]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[32]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[33]  L. Parnetti,et al.  Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis. , 2016, Biomarkers in medicine.